Welcome to our dedicated page for ACCUSTEM SCIENCES news (Ticker: ACUT), a resource for investors and traders seeking the latest updates and insights on ACCUSTEM SCIENCES stock.
AccuStem Sciences Inc (ACUT) is a biotechnology innovator advancing stem cell research and regenerative medicine solutions. This page provides investors and industry professionals with direct access to the company's official announcements, financial updates, and scientific developments.
Track ACUT's progress through curated press releases covering clinical trial milestones, regulatory filings, and strategic partnerships. Our repository ensures you stay informed about advancements in cellular therapies and biotechnological innovations without speculative commentary.
Discover updates across key categories including quarterly earnings reports, intellectual property developments, and collaborative research initiatives. Each entry is timestamped for reference and formatted for clarity across devices.
Bookmark this page for streamlined access to AccuStem's evolving story in medical science. Verify critical information directly from primary sources before making data-driven decisions.
AccuStem Sciences (OTCQB: ACUT) announced that its Chairman, Gabriele Cerrone, has acquired an additional 24,500 shares, bringing his total ownership to 3,855,723 shares. This purchase reflects the Chairman's confidence in the company’s future, as AccuStem focuses on developing innovative molecular testing for cancer diagnostics aimed at improving patient outcomes. The company is dedicated to addressing critical clinical needs throughout cancer screening, treatment, and monitoring.
AccuStem Sciences, Inc. (OTCQB: ACUT) announced the appointment of Sean McDonald to its Board of Directors, increasing the board to five members. McDonald brings extensive experience in building healthcare organizations and securing funding for early-stage companies. Currently the CEO of Ocugenix, he previously held leadership roles at Precision Therapeutics and Automated Healthcare. His background will support AccuStem's mission to innovate cancer diagnostics through genomic testing. CEO Wendy Blosser expressed confidence in McDonald's ability to advance the company's growth strategy.
AccuStem Sciences (OTCQB: ACUT) announced the adjournment of its 2022 annual stockholders' meeting due to a lack of quorum. Originally scheduled for October 10, 2022, the meeting has been rescheduled for October 14, 2022. Proxies from stockholders represent approximately 36% of the outstanding shares. The company aims to solicit additional votes during this period. Stockholders of record as of September 14, 2022, are encouraged to vote by October 13, 2022. AccuStem focuses on enhancing cancer patient outcomes through proprietary molecular testing.
AccuStem Sciences, Inc. (OTCQB: ACUT) has received a new patent (No. 11,441,191) for its innovative StemPrintER test, which stratifies early-stage breast cancer patients based on their recurrence risk. The patented method assesses the stemness of tumors, indicating cancer progression potential and responsiveness to treatment. High stemness patients may face up to four times the risk of distant recurrence compared to those with low stemness. CEO Wendy Blosser emphasized that this patent strengthens their intellectual property portfolio and supports their commitment to healthcare innovation.
AccuStem Sciences, Inc. (OTCQB: ACUT) announced that Chairman Gabriele Cerrone has purchased 20,000 shares of ACUT, increasing his total holdings to 3,821,226 shares. This purchase reflects Cerrone's confidence in the company's trajectory and potential in the life sciences sector focused on cancer treatment. AccuStem is dedicated to improving cancer patient outcomes through innovative solutions and comprehensive care approaches.
FAQ
What is the current stock price of ACCUSTEM SCIENCES (ACUT)?
What is the market cap of ACCUSTEM SCIENCES (ACUT)?
